Key result
The WATCHMAN left atrial appendage closure device provides an effective alternative to long-term anticoagulation for stroke prevention in non-valvular atrial fibrillation patients with high bleeding risk.
Why the study?
Managing patients with atrial fibrillation who have both high stroke risk and high bleeding risk is challenging, prompting the approval and use of the WATCHMAN left atrial appendage closure device as an alternative to long-term anticoagulation.
This review outlines the indications, perioperative management, and future challenges of the WATCHMAN left atrial appendage closure device as an alternative to anticoagulation for AF patients with high bleeding risk in Japan.
Answers are grounded in this paper and cite their sources.
May guide LAA closure in high-bleeding-risk AF; extends Japanese indications review but leaves randomized confirmation open.
高齢化に伴い心房細動(atrial fibrillation: AF)患者は増加し,2050年にはAF有病率が1.1%(103万人)を超えるとされている.AF患者の心原性脳塞栓発症率は年間約5%と高く,90%以上が左心耳由来である.心原性脳塞栓はアテローム血栓性脳梗塞に比べ,梗塞巣が広く重篤化しやすく死亡率や介護度も高くなる.したがってAF患者の治療に際しては抗凝固療法の適応の有無を評価することが推奨される.一方,脳卒中のリスクが高く長期的に抗凝固療法が推奨される患者のうち,出血リスクの高い患者への対応に苦慮することも少なくない.このような患者に対する長期的抗凝固療法の代替として,WATCHMAN左心耳閉鎖デバイス(left atrial appendage closure: LAAC)が2019年9月に日本でも保険適用となった.本稿ではLAACの適応,術前後の流れや併用薬,さらには今後の期待と課題について概説する.
No takes yet. Share an insight, caveat, or question.
Kato et al. (2020) conducted a review in Non-valvular atrial fibrillation. WATCHMAN left atrial appendage closure device vs. Anticoagulation therapy was evaluated. The WATCHMAN left atrial appendage closure device provides an effective alternative to long-term anticoagulation for stroke prevention in non-valvular atrial fibrillation patients with high bleeding risk.
Synapse has enriched 10 related papers. Consider them for comparative context: